Breuer Eun-Kyoung Yim, Murph Mandi M
Department of Systems Biology, The University of Texas MD Anderson Cancer Center, 7435 Fannin Street, Houston, TX, 77054, USA.
Int J Proteomics. 2011 Jan 1;2011. doi: 10.1155/2011/373584.
Technological and scientific innovations over the last decade have greatly contributed to improved diagnostics, predictive models, and prognosis among cancers affecting women. In fact, an explosion of information in these areas has almost assured future generations that outcomes in cancer will continue to improve. Herein we discuss the current status of breast, cervical, and ovarian cancers as it relates to screening, disease diagnosis, and treatment options. Among the differences in these cancers, it is striking that breast cancer has multiple predictive tests based upon tumor biomarkers and sophisticated, individualized options for prescription therapeutics while ovarian cancer lacks these tools. In addition, cervical cancer leads the way in innovative, cancer-preventative vaccines and multiple screening options to prevent disease progression. For each of these malignancies, emerging proteomic technologies based upon mass spectrometry, stable isotope labeling with amino acids, high-throughput ELISA, tissue or protein microarray techniques, and click chemistry in the pursuit of activity-based profiling can pioneer the next generation of discovery. We will discuss six of the latest techniques to understand proteomics in cancer and highlight research utilizing these techniques with the goal of improvement in the management of women's cancers.
过去十年间，技术和科学创新极大地推动了针对女性癌症的诊断、预测模型及预后的改善。事实上，这些领域信息的激增几乎让子孙后代确信癌症治疗效果将持续提升。在此，我们将探讨乳腺癌、宫颈癌和卵巢癌在筛查、疾病诊断及治疗选择方面的现状。在这些癌症的差异中，值得注意的是，乳腺癌基于肿瘤生物标志物有多种预测性检测方法，且在处方治疗方面有复杂的个体化选择，而卵巢癌则缺乏这些工具。此外，宫颈癌在创新的癌症预防疫苗及多种预防疾病进展的筛查选择方面处于领先地位。对于这些恶性肿瘤中的每一种，基于质谱分析、氨基酸稳定同位素标记、高通量酶联免疫吸附测定、组织或蛋白质微阵列技术以及用于基于活性谱分析的点击化学等新兴蛋白质组学技术，都可能引领下一代的发现。我们将讨论六种最新的癌症蛋白质组学理解技术，并重点介绍利用这些技术进行的研究，目标是改善女性癌症的管理。
